An immunotherapy schedule in endocrine-dependent metastatic breast cancer: Correlation between clinical course and immunologic parameters

Journal of Immunotherapy

Volumn 28, Issue 3, 2005, Pages 276-279

  Nicolini, Andrea ^a   Carpi, Angela ^a   Rossi, Giuseppe ^b  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Breast cancer; Immunotherapy; Metastasis

Indexed keywords

ANTIESTROGEN; BETA INTERFERON; LETROZOLE; MELATONIN; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; EOSINOPHIL; FEMALE; FOLLOW UP; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; SIDE EFFECT;

EID: 17844388569     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000156827.67572.53     Document Type: Article

References (17)

1. Nicolini A, Carpi A. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial. Biomed Pharmacother. 2005;59.
2. Danforth D, Tamarkin L, Lippman M. Melatonin increases oestrogen receptor binding activity of human breast cancer cells. Nature. 1983;595:323-325.
3. Lissoni P, Barni S, Tancini G, et al. A randomised study with subcutaneous low-dose interleukin-2 alone vs interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer. 1994;69:196-199.
4. Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer. 1996;8:1340-1343.
5. S-Plus 2000, Data Analysis Products Division, MathSoft, Seattle, WA.
6. Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol. 1998;16:3439-3460.
7. Sledge GW Jr, Hu P, Falkson G, et al. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2000;18:262-266.
8. Gershanovich ML, Garin A, Baltina D. A phase III comparison of two doses of toremifene to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat. 1997;45:251-262.
9. Bonneterre J, Thurlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomised group efficacy and tolerability study. J Clin Oncol. 2000;18:3748-3757.
10. Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 1995;13:2556-2566.
11. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21: 2101-2109.
12. Howell S, Robertson JFR, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004;22:1605-1613.
13. Yamamoto N, Watanabe T, Katsumata N, et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol. 1998;16:2401-2408.
14. Atzpodien J. Home therapy with recombinant interleukin-2 and inrerferon-alpha2b in advanced human malignancies. Lancet. 1990;335:1509-1512.
15. Bernengo MG, Quaglino P, Cappello N, et al. Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients. Melanoma Res. 2000;10:55-65.
16. Lissoni P, Barni S, Ardizzoia A, et al. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin. J Biol Regul Homeost Agents. 1993;7:121-125.
17. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Star-3 signalling in tumour cells. Nat Med. 2004;10:48-54.